Impax Pharmaceuticals Completes Enrollment in ASCEND-PD Phase III Trial of IPX066 in Parkinson's Disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. IPXL, today announced that it has completed enrollment in the ASCEND-PD trial. ASCEND-PD is a multinational Phase III comparative study of IPX066 to carbidopa-levodopa and entacapone in subjects with advanced Parkinson's disease. IPX066 is an investigational extended release capsule formulation of carbidopa-levodopa intended to treat the motor symptoms of Parkinson's disease. IPX066 is being developed in collaboration with GlaxoSmithKline GSK outside the US and Taiwan. Impax plans to provide the top line results for this trial in late August of this year and continues to progress toward filing the new drug application in the fourth quarter of 2011.